News for Clearside Biomedical, Inc. (CLSD)

**media[536533]**

Clearside Biomedical (CLSD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

- Commercial, Clinical and Regulatory Expertise Establish Clearside as the Leader in Suprachoroidal Delivery - - Multiple Events at Asia-Pacific Vitreo-Retina

Clearside Biomedical (CLSD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ETCompany ParticipantsJenny Kobin - IRGeorge Lasezkay -...

Clearside Biomedical (CLSD) delivered earnings and revenue surprises of 28.57% and 310.28%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Clearside Biomedical Inc (CLSD) is set to release its Q3 2024 earnings on Nov 12, 2024. The consensus estimate for Q3 2024 revenue is $0.12 million, and the ear

Clearside Biomedical chief medical officer buys $36,500 in stock

Clearside Biomedical names new board chair

Clearside Biomedical advances CLS-AX into Phase 3 trials

New York-based WW International, Inc. (WW) is up over 54 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

VEGFR2 (vascular endothelial growth factor receptor 2) antagonist is an antineoplastic agent that blocks the binding of natural VEGF ligands, which are...

Growing prevalence of visual impairment propels technological advances in ocular drug delivery...

Clearside Biomedical appoints new board member

The increasing number of diagnosed cases of wet AMD, the current therapies, and the launch of emerging therapies will drive the wet AMD market growth in...

Rezolute, a biotech firm, trading at 50% of cash, is developing RZ358, a potential treatment for hyperinsulinism, with promising phase 3 study prospects.

Here’s how Placental Growth Factors Help in Prediction, Diagnosis, and Treatment of Pre-eclampsia Conditions? FMI Predicts the Market to Surpass US$ 64.6...

/PRNewswire/ -- The "Ocular Drug Delivery Devices Market: Global Market Size, Forecast, Insights, and Competitive Landscape" report has been added to...

- Topline data from proof-of-concept study of VRDN-001 in patients with chronic thyroid eye disease (TED) are expected in June/July 2023 - - Selection...